ledipasvir

Known as: Carbamic Acid, N-((1S)-1-(((6S)-6-(5-(9,9-difluoro-7-(2-((1R,3S,4S)-2-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-azabicyclo(2.2.1)hept-3-yl)-1H-benzimidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro(2.4)hept-5-yl)carbonyl)-2-methylpropyl)-, Methyl Ester, methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate 
An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND Treatment options are limited for patients infected by hepatitis C virus (HCV) with advanced liver disease. We… (More)
  • table 1
  • table 2
  • figure 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND & AIMS There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have… (More)
  • table 1
  • table 7
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Effective treatment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV-1… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
IMPORTANCE There is an unmet need for interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in… (More)
  • table 2
  • table 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Editors' Notes Context Newly approved drug regimens for hepatitis C virus (HCV) treatment seem more efficacious and safer than… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
UNLABELLED Patients with hepatitis C virus (HCV) infection and cirrhosis are underrepresented in clinical trials of interferon… (More)
  • table 4
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Interferon-based treatment is not suitable for many patients with hepatitis C virus (HCV) infection because of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS We evaluated an all-oral regimen comprising the nucleotide polymerase inhibitor sofosbuvir (SOF) with the NS5A… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?